Reaction

Tumour Pain reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,306 reports · 57 co-occurring drugs

As of the last recalculation, Tumour Pain appears in 1,306 FAERS reports alongside 57 co-occurring drug terms. The strongest observed disproportionality signal is LOPERAMIDE HYDROCHLORIDE ORAL (PRR 43.0).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Loperamide Hydrochloride Oral	27	43.0	43.1
Lanreotide Acetate	20	41.3	41.4
Ado-Trastuzumab Emtansine	20	38.4	38.5
Loperamide Hcl	27	34.1	34.2
Octreotide Acetate	59	32.1	32.2
Pazopanib Hydrochloride	50	30.6	30.6
Pertuzumab	45	27.3	27.3
Regorafenib	18	25.0	25.1
Cabozantinib	68	23.7	23.8
Sunitinib Malate	53	22.3	22.4
Everolimus	63	20.7	20.7
Ribociclib	39	20.3	20.3
Nivolumab	108	19.3	19.3
Everolimus Tablets	20	19.3	19.3
Ipilimumab	50	19.2	19.2
Lenvatinib	38	19.0	19.0
Fosaprepitant Dimeglumine	16	18.8	18.8
Sorafenib	23	17.9	18.0
Prochlorperazine Maleate	10	17.4	17.4
Aprepitant	19	16.6	16.6
Vismodegib	9	16.2	16.2
Trastuzumab	66	16.1	16.1
Cyclobenzaprine Hydrochloride	8	14.3	14.3
Loperamide Hydrochloride	38	13.9	13.9
Fulvestrant	28	13.8	13.8
Selinexor	7	13.0	13.0
Capecitabine	63	11.5	11.5
Cetuximab	22	11.4	11.4
Atezolizumab	26	10.9	10.9
Granisetron Hydrochloride	7	10.7	10.7
Axitinib	13	10.7	10.7
Metoclopramide	34	10.1	10.1
Erlotinib	6	9.9	9.9
Vemurafenib	7	9.3	9.3
Avapritinib	7	9.3	9.3
Paclitaxel	54	9.0	9.0
Erlotinib Hydrochloride	7	9.0	9.0
Docetaxel Anhydrous	34	8.2	8.2
Docetaxel	34	8.2	8.2
Polatuzumab Vedotin	5	8.2	8.2
Imatinib Mesylate	14	8.1	8.1
Niraparib	11	8.0	8.0
Gemcitabine	19	7.8	7.8
Pembrolizumab	49	7.7	7.7
Paclitaxel (Aibumin-Bound)	38	7.6	7.6
Bevacizumab	56	7.5	7.5
Palbociclib	43	7.4	7.4
Panitumumab	7	7.2	7.2
Dabrafenib	9	6.8	6.9
Pemetrexed Disodium	16	6.8	6.8
Pemetrexed	9	6.7	6.7
Fam-Trastuzumab Deruxtecan-Nxki	4	6.3	6.3
Gemcitabine Hydrochloride	20	6.1	6.1
Abiraterone	5	5.9	5.9
Durvalumab	7	5.5	5.5
Crizotinib	4	5.0	5.0
Pegfilgrastim	24	3.9	3.9

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.